These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35608625)

  • 21. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
    Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
    Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.
    Hendrickson WK; Xie G; Rahn DD; Amundsen CL; Hokanson JA; Bradley M; Smith AL; Sung VW; Visco AG; Luo S; Jelovsek JE
    Neurourol Urodyn; 2022 Jan; 41(1):432-447. PubMed ID: 34859485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic use, best practice statement adherence, and UTI rate for intradetrusor onabotulinumtoxin-A injection for overactive bladder: A multi-institutional collaboration from the SUFU Research Network (SURN).
    Shapiro K; Anger J; Cameron AP; Chung D; Daignault-Newton S; Ippolito GM; Lee U; Mourtzinos A; Padmanabhan P; Smith AL; Suskind AM; Tenggardjaja C; Van Til M; Brucker BM
    Neurourol Urodyn; 2024 Feb; 43(2):407-414. PubMed ID: 38032120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
    Giannantoni A; Gubbiotti M; Rubilotta E; Balzarro M; Antonelli A; Bini V
    Minerva Urol Nephrol; 2022 Oct; 74(5):625-635. PubMed ID: 33769020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
    Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
    Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
    McCammon K; Gousse A; Kohan A; Glazier D; Gruenenfelder J; Bai Z; Patel A; Hale D
    Female Pelvic Med Reconstr Surg; 2021 Jul; 27(7):450-456. PubMed ID: 32665528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
    Stamm AW; Adelstein SA; Chen A; Lucioni A; Kobashi KC; Lee UJ
    J Urol; 2018 Oct; 200(4):809-814. PubMed ID: 29653162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
    Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
    World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
    Chermansky CJ; Richter HE; Jacoby K; Titanji W; Jenkins B; Geib T; Brucker BM
    J Urol; 2022 Oct; 208(4):855-862. PubMed ID: 35830550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial.
    Komar A; Bretschneider CE; Mueller MG; Lewicky-Gaupp C; Collins S; Geynisman-Tan J; Tavathia M; Kenton K
    Obstet Gynecol; 2021 Jan; 137(1):12-20. PubMed ID: 33278293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens.
    Houman J; Moradzadeh A; Patel DN; Asanad K; Anger JT; Eilber KS
    Int Urogynecol J; 2019 May; 30(5):701-704. PubMed ID: 30074062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip.
    Derisavifard S; Giusto LL; Zahner P; Rueb JJ; Goldman HB
    Urology; 2020 Jan; 135():38-43. PubMed ID: 31600558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Duration of Antibiotic Prophylaxis on Incidence of UTI after OnabotulinumtoxinA Injection.
    Martin S; Zillioux J; Goldman HB; Slopnick E
    Urology; 2022 Aug; 166():140-145. PubMed ID: 35595075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
    Sievert KD; Chapple C; Herschorn S; Joshi M; Zhou J; Nardo C; Nitti VW
    Int J Clin Pract; 2014 Oct; 68(10):1246-56. PubMed ID: 24754838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis.
    Getaneh FW; Simhal R; Sholklapper T; Melvin E; Dorris CS; Chou J; Richter LA; Dieter A
    Int Urogynecol J; 2024 Jan; 35(1):19-29. PubMed ID: 37938397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.